NII-108

NII-108
Drug name	NII-108

NII-108 NII-108 is an experimental small-molecule therapeutic investigated for neuropsychiatric and neurodegenerative indications. The agent has been examined in preclinical models and early-phase human trials at academic centers and by biotechnology firms collaborating with pharmaceutical companies and government research institutes. Development has involved multidisciplinary teams from universities, contract research organizations, venture capital firms, and regulatory agencies.

Chemical identity

NII-108 is described by its systematic IUPAC name and assigned identifiers by chemical registries; the compound appears in cheminformatics databases alongside analogs characterized by heterocyclic cores and lipophilic substituents. Structural features have been compared with scaffolds in medicinal chemistry literature associated with kinase inhibitors and ion channel modulators, and cheminformatics analyses reference entries in supplier catalogs, patent families, and open chemical repositories. Researchers have cross-referenced NII-108 against lead series reported in academic journals from institutions such as Harvard University, Stanford University, Massachusetts Institute of Technology, University of Cambridge, and University of Oxford to position the molecule within scaffold-hopping campaigns.

Pharmacology and mechanism of action

Pharmacological characterization of NII-108 has involved in vitro assays at contract assay providers and academic laboratories affiliated with Johns Hopkins University, University of California, San Francisco, Yale University, and Columbia University. Binding studies have been performed using radioligand displacement and surface plasmon resonance platforms common to groups at National Institutes of Health and University of Pennsylvania. Mechanistic hypotheses under investigation include modulation of intracellular signaling cascades reported in pathways studied at Cold Spring Harbor Laboratory, interaction with membrane proteins profiled in datasets from European Bioinformatics Institute, and functional effects on neuronal excitability assessed in preparations used by researchers at Salk Institute and Max Planck Society laboratories. Comparative pharmacology cites examples from compounds developed by firms such as Pfizer, Roche, Novartis, GlaxoSmithKline, and AstraZeneca.

Synthesis and chemical properties

Synthetic routes to NII-108 have been developed by medicinal chemistry teams and contract manufacturers with expertise like that of Evonik Industries, BASF, and university spin-outs. Reports discuss stepwise formation of heterocycles using palladium-catalyzed cross-coupling reactions popularized in literature from University of Tokyo, ETH Zurich, and University of California, Berkeley. Analytical characterization employed techniques standardized by organizations such as American Chemical Society and Royal Society of Chemistry, including nuclear magnetic resonance spectroscopy and mass spectrometry platforms used in core facilities at Imperial College London and University of Edinburgh. Physicochemical profiling—solubility, lipophilicity, and stability—drew on methods reported in monographs from European Medicines Agency and measurement systems deployed by Thermo Fisher Scientific and Agilent Technologies.

Preclinical studies

Efficacy and safety evaluations in cell-based systems and animal models were conducted in collaboration with laboratories at National Institute of Mental Health, Scripps Research, Riken, and veterinary research units associated with University of Cambridge. Behavioral pharmacology used assays and paradigms developed at University College London and McGill University to assess cognition and affective endpoints, while toxicology followed guidelines from Organisation for Economic Co-operation and Development and employed pathology services like those at Covance and Charles River Laboratories. Pharmacokinetic and biodistribution studies referenced imaging and bioanalytical platforms used at Mayo Clinic and Karolinska Institutet. Preclinical manuscripts compare outcomes to benchmark compounds reported by groups at Columbia University Irving Medical Center and biotech companies such as Biogen and Amgen.

Clinical development

Early-phase clinical trials have been coordinated through academic medical centers, clinical research organizations, and industry partners including collaborations similar to those between University of Pennsylvania Health System and biotechnology firms. Phase 1 protocols referenced design standards from Food and Drug Administration guidance documents and employed trial registries and data capture systems used by ClinicalTrials.gov and networks affiliated with European Medicines Agency. Investigators from institutions like Massachusetts General Hospital, Brigham and Women's Hospital, Karolinska University Hospital, and Guy's and St Thomas' NHS Foundation Trust have been cited in investigator-initiated studies. Trial endpoints and biomarkers draw on methodologies established at National Institute on Aging and consortiums such as Alzheimer's Disease Neuroimaging Initiative.

Safety and adverse effects

Safety assessments have been reported using terminology and grading scales promulgated by Common Terminology Criteria for Adverse Events and monitored by institutional review boards at centers including Mayo Clinic and Cleveland Clinic. Adverse event profiles in early reports have been contextualized with safety data from drug classes developed by companies such as Eli Lilly and Company, Johnson & Johnson, and Takeda Pharmaceutical Company Limited. Laboratory safety monitoring employed assays and clinical chemistry referencing standards from World Health Organization and clinical laboratories affiliated with Johns Hopkins Hospital and Mount Sinai Health System.

Regulatory status and patents

Regulatory interactions for NII-108 have referenced procedures at the Food and Drug Administration, European Medicines Agency, and national competent authorities in jurisdictions associated with industrial partners and research institutions. Intellectual property filings appear in patent families managed via patent law firms and technology transfer offices linked to universities such as University of California and University of Cambridge, and are examined in patent databases used by analysts at World Intellectual Property Organization and European Patent Office. Commercial development strategies reflect precedents set by licensing deals and mergers among firms like Gilead Sciences and Regeneron Pharmaceuticals.

Category:Experimental drugs